Multifaceted intervention to reduce haemodialysis catheter related bloodstream infections: REDUCCTION stepped wedge, cluster randomised trial.


Journal

BMJ (Clinical research ed.)
ISSN: 1756-1833
Titre abrégé: BMJ
Pays: England
ID NLM: 8900488

Informations de publication

Date de publication:
12 04 2022
Historique:
entrez: 13 4 2022
pubmed: 14 4 2022
medline: 15 4 2022
Statut: epublish

Résumé

To identify whether multifaceted interventions, or care bundles, reduce catheter related bloodstream infections (CRBSIs) from central venous catheters used for haemodialysis. Stepped wedge, cluster randomised design. 37 renal services across Australia. All adults (age ≥18 years) under the care of a renal service who required insertion of a new haemodialysis catheter. After a baseline observational phase, a service-wide, multifaceted intervention bundle that included elements of catheter care (insertion, maintenance, and removal) was implemented at one of three randomly assigned time points (12 at the first time point, 12 at the second, and 13 at the third) between 20 December 2016 and 31 March 2020. The primary endpoint was the rate of CRBSI in the baseline phase compared with intervention phase at the renal service level using the intention-to-treat principle. 1.14 million haemodialysis catheter days of use were monitored across 6364 patients. Patient characteristics were similar across baseline and intervention phases. 315 CRBSIs occurred (158 in the baseline phase and 157 in the intervention phase), with a rate of 0.21 per 1000 days of catheter use in the baseline phase and 0.29 per 1000 days in the intervention phase, giving an incidence rate ratio of 1.37 (95% confidence interval 0.85 to 2.21; P=0.20). This translates to one in 10 patients who undergo dialysis for a year with a catheter experiencing an episode of CRBSI. Among patients who require a haemodialysis catheter, the implementation of a multifaceted intervention did not reduce the rate of CRBSI. Multifaceted interventions to prevent CRBSI might not be effective in clinical practice settings. Australia New Zealand Clinical Trials Registry ACTRN12616000830493.

Identifiants

pubmed: 35414532
doi: 10.1136/bmj-2021-069634
pmc: PMC9002320
doi:

Types de publication

Journal Article Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e069634

Informations de copyright

© Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: All authors have completed the ICMJE uniform disclosure form at www.icmje.org/disclosure-of-interest/ and declare: support from the organisations listed in the funding statement for the submitted work; no financial relationships with any organisations that might have an interest in the submitted work in the previous three years; no other relationships or activities that could appear to have influenced the submitted work.

Références

N Engl J Med. 2006 Dec 28;355(26):2725-32
pubmed: 17192537
Clin Trials. 2004;1(3):297-305
pubmed: 16279255
Nephrology (Carlton). 2019 Aug;24(8):827-834
pubmed: 30267459
Contemp Clin Trials. 2007 Feb;28(2):182-91
pubmed: 16829207
BMJ Qual Saf. 2016 Feb;25(2):118-29
pubmed: 26183714
JAMA Intern Med. 2013 Dec 9-23;173(22):2039-46
pubmed: 23999949
JAMA Intern Med. 2016 Dec 01;176(12):1843-1854
pubmed: 27775764
J Vasc Surg. 2017 Mar;65(3):766-774
pubmed: 28236919
Can J Kidney Health Dis. 2016 Sep 27;3:2054358116669129
pubmed: 28270921
Clin J Am Soc Nephrol. 2017 Jul 7;12(7):1139-1146
pubmed: 28663227
Nephrology (Carlton). 2013 Nov;18(11):701-5
pubmed: 23855977
Implement Sci. 2017 Nov 29;12(1):142
pubmed: 29187217
Am J Kidney Dis. 2014 Feb;63(2):259-67
pubmed: 24295613
Clin J Am Soc Nephrol. 2011 Sep;6(9):2247-52
pubmed: 21737847
Clin Infect Dis. 2009 Jul 1;49(1):1-45
pubmed: 19489710
Kidney360. 2020 Jun 02;1(8):746-754
pubmed: 35372959
Semin Dial. 2008 Jan-Feb;21(1):24-8
pubmed: 18251954
Crit Care Med. 2012 Nov;40(11):2933-9
pubmed: 22890251
Clin Infect Dis. 2011 May;52(9):e162-93
pubmed: 21460264

Auteurs

Sradha Kotwal (S)

George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia skotwal@georgeinstitute.org.au.
Prince of Wales Hospital, University of New South Wales, Sydney, NSW, Australia.

Alan Cass (A)

Menzies School of Health Research, Charles Darwin University, Darwin, NT, Australia.

Sarah Coggan (S)

George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.

Nicholas A Gray (NA)

Sunshine Coast University Hospital, Birtinya, QLD, Australia.
Department of Health and Behavioural Science,University of the Sunshine Coast, Sippy Downs, QLD, Australia.

Stephen Jan (S)

George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.

Stephen McDonald (S)

ANZDATA Registry, South Australia Health and Medical Research Institute, Adelaide, SA, Australia.
Adelaide Medical School, University of Adelaide, Adelaide, SA, Australia.
Renal Unit, Royal Adelaide Hospital, Adelaide, SA, Australia.

Kevan R Polkinghorne (KR)

Department of Epidemiology and Preventive Medicine, Monash University, VIC, Australia.
Departments of Nephrology and Medicine, Monash Medical Centre, Monash University, VIC, Australia.

Kris Rogers (K)

George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.
Graduate School of Health, University of Technology Sydney, Sydney, NSW, Australia.
School of Population Health, University of New South Wales, Sydney, NSW, Australia.

Girish Talaulikar (G)

Renal Services, ACT Health, Canberra, ACT, Australia.

Gian Luca Di Tanna (GL)

George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.

Martin Gallagher (M)

George Institute for Global Health, University of New South Wales, Sydney, NSW, Australia.
South Western Sydney Clinical School, University of New South Wales, NSW, Sydney, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH